Determinants of infarct size after thrombolytic treatment in acute myocardial infarction

Both experimental and single-center clinical studies have shown that myocardium at risk, residual collateral flow, and duration of coronary occlusion are important determinants of final infarct size. The purpose of this study was to replicate these results on a multicenter basis to demonstrate that perfusion imaging using different camera and computer systems can provide reliable assessments of myocardium at risk and collateral flow. Sequential tomographic myocardial perfusion imaging with technetium-99 (Tc-99m) sestamibi was performed in 74 patients with first time myocardial infarction, who were enrolled in a multicenter, randomized, double-blind, placebo-controlled pilot study of poloxamer 188 as ancillary therapy to thrombolysis. All patients underwent thrombolysis within 6 hours of the onset of chest pain. Tc-99m sestamibi was injected intravenously at the initiation of thrombolytic therapy, and tomographic imaging was performed 1 to 6 hours later to assess myocardium at risk. Collateral flow was estimated noninvasively from the acute sestamibi images by 3 methods that assess the severity of the perfusion defect. Final infarct size was determined at hospital discharge by a second sestamibi study. Myocardium at risk (r = 0.61, p <0.0001) and radionuclide estimates of collateral flow (r = 0.58 to 0.66, all p <0.0001) were significantly associated with final infarct size. These associations were independent of the treatment center. On a multivariate basis, myocardium at risk (p = 0.003), the radionuclide estimate of collateral flow (p = 0.03), and treatment arm (p = 0.04) were all independent determinants of infarct size. Time to thrombolytic therapy showed only a trend (p = 0.10). The treatment center was not significant (p = 0.42). Myocardium at risk and collateral flow are important determinants of infarct size that are independent of treatment center. Tomographic imaging with Tc-99m sestamibi can provide noninvasive assessments of these parameters in multicenter trials of thrombolytic therapy.

Variability of myocardium at risk for acute myocardial infarction

The objective of this study was to assess the variability in myocardium at risk and relate this to coronary angiographic variables. One hundred ninety-seven patients with > or = 1-mm ST-segment elevation in 2 contiguous electrocardiographic leads, without prior myocardial infarction, were injected with technetium-99m sestamibi acutely before reperfusion therapy. The perfusion defect was quantified to determine myocardium at risk for infarction. Patients underwent coronary angiography to determine the infarct-related artery and to classify the occlusion as proximal or not proximal. Collateral and anterograde (Thrombolysis In Myocardial Infarction [TIMI] trial) flow were assessed in a subset of 83 patients with angiography before direct angioplasty. Myocardium at risk for infarction in the distribution of the left anterior descending coronary artery was significantly greater (p <0.0001) than that in the circumflex or right coronary artery. In the left anterior descending coronary artery distribution, myocardium at risk for infarction was significantly larger for proximal occlusions (p <0.0001). There was a trend toward greater myocardium at risk for infarction of proximal occlusions (p = 0.14) of the left circumflex but not for proximal occlusions in the right coronary artery distribution (p = 0.47). Multivariate analysis revealed that the infarct-related artery (p <0.0001), TIMI flow (p = 0.0002), and proximal location (p = 0.09) in the infarct-related artery were independent predictors of myocardium at risk for infarction. Thus, infarct-related artery, TIMI flow, and proximal location of occlusion in the infarct-related artery influence the myocardium at risk for infarction, which is highly variable for given location of occlusion.

Pulmonary function monitoring during adenosine myocardial perfusion scintigraphy in patients with chronic obstructive pulmonary disease

OBJECTIVE

To determine whether adenosine could be safely administered to patients with chronic obstructive pulmonary disease (COPD) for coronary vasodilatation during perfusion scintigraphy without causing bronchospasm.

MATERIAL AND METHODS

The study was divided into two phases. In the monitoring phase, patients with COPD were pretreated with an inhaled bronchodilator (albuterol) and had pulmonary function monitored during the infusion of a graduated dose of adenosine. Eligibility for entry into this phase of the study was determined on the basis of results of pulmonary function testing (PFT) during resting. Once we had shown that adenosine could be safely administered to patients with COPD, an implementation phase was begun. Entry did not require resting PFT, and patients were administered adenosine without monitoring of pulmonary function. Differences between patients with normal pulmonary function or mild COPD and those with more severe COPD were analyzed statistically.

RESULTS

Of 94 patients entered into the monitoring phase, none had obvious bronchospasm. The dosage of adenosine was reduced in four patients because of a decrease in forced expiratory volume in 1 second (FEV1) of 20% in comparison with baseline (FEV1 before administration of albuterol). The mean FEV1 decreased slightly from 1.83 L after administration of albuterol to 1.78 L during the maximal adenosine dose. Patients with a remote history of asthma, positive result of a methacholine challenge test, or mild COPD (FEV1 60 to 80% of the maximal predicted value for age) did not differ significantly in their response to infusion of adenosine from those with moderate or severe COPD (FEV1 30 to 59% of the maximum predicted for age). Of 117 patients in the implementation phase, 2 had bronchospasm during infusion of adenosine that was quickly terminated by stopping the administration in one patient and reducing the dose of adenosine in the other.

CONCLUSION

This study shows that adenosine can be safely administered intravenously to selected patients with known or suspected COPD to produce coronary vasodilatation for myocardial perfusion imaging. Patients who are within the guidelines established for this study should be considered for adenosine coronary vasodilatation with use of bronchodilator pretreatment, a graduated dose of adenosine, and regular chest auscultation during the infusion.

Comparison of measurement of left ventricular ejection fraction by Tc-99m sestamibi first-pass angiography with electron beam computed tomography in patients with anterior wall acute myocardial infarction

The goal of this study was to compare measurements of left ventricular (LV) ejection fraction (EF) by first-pass radionuclide angiography ("first-pass angiography") using technetium-99m (Tc-99m) sestamibi with those by contrast-enhanced electron beam computed tomography ("electron beam tomography") as a reference technique in patients with an anterior wall acute myocardial infarction (AMI). Twenty-five patients with first Q-wave anterior wall AMI underwent paired electron beam tomographic and first-pass angiographic studies (mean, 1 day apart). Fourteen patients had 2 sets of measurements of the LVEF obtained by both methods (separated by at least 6 weeks), for a total of 39 paired measurements. LVEF by electron beam tomography was calculated from absolute systolic and diastolic LV chamber volumes. LV volumes by electron beam tomography were 199 +/- 51 ml at end-diastole and 111 +/- 42 ml at end-systole. Mean LVEF was 45 +/- 11% by first-pass tomography and 46 +/- 9% by electron beam tomography. The linear correlation coefficient between both methods was 0.82 (p <0.0001), with slope = 1.0, y-intercept = -1.1, and SEE = 6.1. The mean difference between the 2 methods was -0.7 +/- 6.0 EF units (p = 0.75). The correlation between the differences and means of both methods was 0.34 (p = 0.04), indicating a trend for first-pass angiography to overestimate LVEF in the higher range. LVEFs measured by first-pass angiography in patients with abnormal LV geometry and contraction patterns caused by anterior wall AMI agree well with those measured by electron beam tomography in the clinically relevant range.

Brachydactyly type B: linkage to chromosome 9q22 and evidence for genetic heterogeneity

Brachydactyly type B (BDB), an autosomal dominant disorder, is the most severe of the brachydactylies and is characterized by hypoplasia or absence of the terminal portions of the index to little fingers, usually with absence of the nails. The thumbs may be of normal length but are often flattened and occasionally are bifid. The feet are similarly but less severely affected. We have performed a genomewide linkage analysis of three families with BDB, two English and one Portugese. The two English families show linkage to the same region on chromosome 9 (combined multipoint maximum LOD score 8.69 with marker D9S257). The 16-cM disease interval is defined by recombinations with markers D9S1680 and D9S1786. These two families share an identical disease haplotype over 18 markers, inclusive of D9S278-D9S280. This provides strong evidence that the English families have the same ancestral mutation, which reduces the disease interval to <12.7 cM between markers D9S257 and D9S1851 in chromosome band 9q22. In the Portuguese family, we excluded linkage to this region, a result indicating that BDB is genetically heterogeneous. Reflecting this, there were atypical clinical features in this family, with shortening of the thumbs and absence or hypoplasia of the nails of the thumb and hallux. These results enable a refined classification of BDB and identify a novel locus for digit morphogenesis in 9q22.

A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators

BACKGROUND

Nearly half of patients hospitalized with unstable angina eventually receive a non-cardiac-related diagnosis, yet 5 percent of patients with myocardial infarction are inappropriately discharged from the emergency department. We evaluated the safety, efficacy, and cost of admission to a chest-pain observation unit (CPU) located in the emergency department for such patients.

METHODS

We performed a community-based, prospective, randomized trial of the safety, efficacy, and cost of admission to a CPU as compared with those of regular hospital admission for patients with unstable angina who were considered to be at intermediate risk for cardiovascular events in the short term. A total of 424 eligible patients were randomly assigned to routine hospital admission (a monitored bed under the care of the cardiology service) or admission to the CPU (where patients were cared for according to a strict protocol including aspirin, heparin, continuous ST-segment monitoring, determination of creatine kinase isoenzyme levels, six hours of observation, and a study of cardiac function). The CPU was managed by the emergency department staff. Patients whose test results were negative were discharged, and the others were hospitalized. Primary outcomes (nonfatal myocardial infarction, death, acute congestive heart failure, stroke, or out-of-hospital cardiac arrest) and use of resources were compared between the two groups.

RESULTS

The 212 patients in the hospital-admission group had 15 primary events (13 myocardial infarctions and 2 cases of congestive heart failure), and the 212 patients in the CPU group had 7 events (5 myocardial infarctions, 1 death from cardiovascular causes, and 1 case of congestive heart failure). There was no significant difference in the rate of cardiac events between the two groups (odds ratio for the CPU group as compared with the hospital-admission group, 0.50; 95 percent confidence interval, 0.20 to 1.24). No primary events occurred among the 97 patients who were assigned to the CPU and discharged. Resource use during the first six months was greater among patients assigned to hospital admission than among those assigned to the CPU (P<0.01 by the rank-sum test).

CONCLUSIONS

A CPU located in the emergency department can be a safe, effective, and cost-saving means of ensuring that patients with unstable angina who are considered to be at intermediate risk of cardiovascular events receive appropriate care.

Actinomyces naeslundii genospecies 1 and 2 express different binding specificities to N-acetyl-beta-D-galactosamine, whereas Actinomyces odontolyticus expresses a different binding specificity in colonizing the human mouth

A total of 102 strains of Actinomyces were isolated from teeth, buccal mucosa and tongue in eight individuals. The isolates were characterized by multivariate statistical analyses of phenotypic characteristics, serotyping and binding to beta-linked galactosamine (N-acetyl-beta-D-galactosamine) and acidic proline-rich protein structures. Based on these characteristics, isolates were classified into three major groups: (i) Isolates of Actinomyces naeslundii genospecies 2 were the dominant species on teeth and buccal mucosa and bound commonly to N-acetyl-beta-D-galactosamine (63 of 63 isolates) and acidic proline-rich proteins (63 of 63 isolates), regardless of tissue origin. They all exhibited a N-acetyl-beta-D-galactosamine binding specificity signified by N-acetyl-beta-D-galactosamine-inhibitable coaggregation with the streptococcal strains LVG1, GVE1, 24892 and MPB1; (ii) Isolates of A. naeslundii genospecies 1 were prevalent on teeth in certain individuals and bound commonly to N-acetyl-beta-D-galactosamine (20 of 20 isolates), but less commonly to acidic proline-rich proteins (5 of 20 isolates). They all possessed another N-acetyl-beta-D-galactosamine specificity, i.e. N-acetyl-beta-D-galactosamine-inhibitable coaggregation with the same streptococcal strains except for strain MPB1; (iii) Isolates of Actinomyces odontolyticus, the dominant species on the tongue (17 of 19 isolates), bound commonly to unknown structures on streptococci (17 of 19 isolates) but rarely to N-acetyl-beta-D-galactosamine (2 of 19 isolates) or acidic proline-rich proteins (3 of 19 isolates). In conclusion, A. naeslundii genospecies 1 and 2 exhibit different patterns of N-acetyl-beta-D-galactosamine and acidic proline-rich protein specificities to colonize dental and buccal mucosa surfaces, whereas A. odontolyticus utilizes another specificity to colonize the tongue.

The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms

BACKGROUND

Exercise stress testing in patients with abdominal aortic aneurysms may cause enlargement or rupture of aneurysms.

OBJECTIVE

To evaluate the safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms.

DESIGN

Retrospective descriptive study.

SETTING

Tertiary care center.

PATIENTS

262 patients who had abdominal aortic aneurysms more than 4 cm in diameter and underwent treadmill exercise stress testing.

MEASUREMENTS

Pain after stress testing, rupture of the aneurysm or death, aneurysm size, and exercise stress test results.

RESULTS

The average aneurysm diameter was 5.5 +/- 1.1 cm. One patient with a 6.1-cm aneurysm was found to have a contained rupture 12 hours after stress testing. The event rate for aneurysm rupture was 0.4% (95% CI, 0.0% to 2.1%). No deaths or other negative outcomes were documented.

CONCLUSION

Despite theoretical concerns, exercise stress testing of patients with abdominal aortic aneurysms seems to be safe and is associated with a low incidence of acute adverse events.

Accuracy of single-photon emission computed tomography myocardial perfusion imaging in patients with stents in native coronary arteries

Strategies to noninvasively evaluate patients after coronary stenting have not been evaluated. To determine the accuracy of single-photon emission computed tomography (SPECT) myocardial perfusion imaging in patients after coronary stenting, 209 patients who had undergone stenting followed by late stress SPECT myocardial perfusion imaging were evaluated. Quantitative coronary angiography was performed in 33 patients following SPECT imaging. SPECT restenosis was defined as a reversible or fixed defect within the stented vascular territory. Angiographic restenosis was examined using 2 definitions: total area narrowing > or =50% or > or =70% of the stent site or stented artery. The SPECT and angiographic findings were concordant in 22 of 33 stented vascular territories using the 50% definition of restenosis and in 29 of 33 stented territories using the 70% definition. Use of the 70% definition of restenosis resulted in improved accuracy of SPECT to detect a significant stenosis in the stented artery. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of SPECT were 95%, 73%, 88%, 89%, and 88% respectively. In patients with positive SPECT scans, the most significant stenosis in the stented artery was outside the stent site in 50% of cases. SPECT imaging appears to be accurate to predict significant stenosis in the stented artery, although the most severe stenosis is frequently distant from the stent site.

Sex differences in ventricular function in patients with right bundle branch block

BACKGROUND

Left ventricular function in patients with right bundle branch block is variable and depends on the population under study. This study assessed the implications of right bundle branch block for the estimation of resting left ventricular function in patients with right bundle branch and suspected coronary artery disease.

METHODS AND RESULTS

Seventy-four patients with right bundle branch block, symptoms suggestive of coronary artery disease, and no electrocardiographic Q waves were compared with 649 patients with entirely normal electrocardiograms to assess the implications of right bundle branch block on resting left ventricular function. Resting ejection fraction was determined by radionuclide ventriculography. Patients with right bundle branch block were older (mean 65.0+/-10.2 years vs 53.8+/-11.1; P< .001) and had a lower mean ejection fraction (60%+/-11% vs 63%+/-9%; P< .005) compared with patients with normal electrocardiograms. There was a highly significant interaction between right bundle branch block and sex with respect to resting ejection fraction (P< .001). The mean ejection fraction for men with right bundle branch block was 57%+/-10% (17% with abnormal resting ejection fraction) compared with 62%+/-8% (7% with abnormal resting ejection fraction) for normal men. In contrast, the mean ejection fraction for women with right bundle branch block was 68%+/-9% (0% with abnormal resting ejection fraction) compared with 65%+/-9% (5% with abnormal resting ejection fraction) for normal women.

CONCLUSIONS

Male patients with right bundle branch block and symptoms suggestive of coronary artery disease have a lower resting ejection fraction than mole patients with normal electrocardiograms. This difference is not seen in female patients.

Twelve-year outcome of patients with an abnormal exercise radionuclide left ventricular angiogram and angiographically insignificant coronary artery disease

This study examines the long-term prognosis of patients with an abnormal exercise radionuclide angiogram in the absence of significant angiographic coronary artery disease (CAD). In general, patients without significant CAD have an excellent prognosis, but the long-term outcome for the subset of patients with an "ischemic" exercise test is not known. In this study, 161 patients with normal coronary arteries or insignificant CAD (< 50% left main and < 70% left anterior descending, left circumflex, or right), resting left ventricular (LV) ejection fraction > or = 0.50, and an abnormal exercise radionuclide angiogram (LV ejection fraction that decreased with exercise or peak exercise LV ejection fraction < 0.60) were followed for a median duration of 11.3 years. The mean delta LV ejection fraction was -0.07, 98 patients (61%) had a decrease in LV ejection fraction of > or = 5 units, and 40 patients (25%) had peak exercise LV ejection fraction < 0.50. During follow-up there were 19 deaths (only 1 of which was cardiac), 7 nonfatal myocardial infarctions, and 9 revascularization procedures. At 12 years, overall survival was 88%, better than the expected survival for the age- and sex-matched general population. Survival free of cardiac death or myocardial infarction was 94% and survival free of any cardiac event including revascularization was 88%. Thus, patients with an abnormal exercise radionuclide angiogram but without significant CAD have an excellent long-term prognosis.

Intravenous adenosine and lidocaine in patients with acute myocardial infarction

OBJECTIVES

A pilot study was designed to assess the safety of combined intravenous adenosine and lidocaine in patients with acute myocardial infarction and to estimate the likelihood of a beneficial effect on final infarct size.

BACKGROUND

Adenosine plus lidocaine reduces infarct size in animals, but the safety and efficacy in human beings is unknown.

METHODS AND RESULTS

Adenosine (70 microg/kg per minute intravenous infusion) plus lidocaine (1 mg/kg intravenous bolus injection and 2 mg/kg per minute infusion) was given to 45 patients with acute myocardial infarction. Patients underwent immediate balloon angioplasty without preceding thrombolytic therapy. Myocardial perfusion defects were measured with serial technetium 99m sestamibi studies. One patient developed persisting hypotension in conjunction with a large inferolateral myocardial infarction. Transient hypotension in three other patients resolved with a reduction in adenosine. Advanced atrioventricular block was never observed. Other adverse events (including atrial fibrillation, ventricular tachyarrhythmia, bradycardia, and respiratory distress) occurred at low frequencies, as expected for patients with acute myocardial infarction. An initial median perfusion defect of 45% of the left ventricle (60% for anterior infarction, 17% for nonanterior infarction) was observed. At hospital discharge (mean +/- SD = 4.3 +/- 2.1 days) the median value was 12%, and at 8 +/- 4 weeks it was 3% (7% for anterior infarction, 0% for nonanterior infarction); 14 patients had no measurable follow-up. Compared with historical control patients, prehospital discharge measurements were not different but late perfusion defects were improved.

CONCLUSIONS

Treatment with intravenous adenosine and lidocaine during acute myocardial infarction has sufficient safety and potential for improved myocardial salvage. Randomized studies are justified.

Reversible perfusion defects on exercise tomographic thallium imaging in patients with and without collateral flow

A consecutive series of patients underwent exercise thallium imaging and coronary angiography that identified single-vessel right coronary artery disease. Redistribution in the left anterior descending territory was significantly associated with the presence of left-to-right collaterals, whereas collaterals were significantly less frequent in individuals who did not exhibit redistribution.

Usefulness of technetium-99m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction

In this multicenter study, 249 patients who underwent tomographic technetium-99m sestamibi infarct size measurement at hospital discharge were followed up for a median duration of 7 months. Infarct size was significantly associated with mortality (chi-square = 5.8, p = 0.02) and could stratify patients into lower and higher risk subsets: 1-year mortality 2% for infarct size < 14% versus 8% for infarct size > or = 14% of the left ventricle.

Correlation of resting first-pass left ventricular ejection fraction and resting myocardial infarct size

This study determined the correlation between the extent of the resting perfusion defect by technetium-99m sestamibi tomographic imaging and the first-pass left ventricular (LV) ejection fraction (EF). A total of 1,955 patients underwent technetium-99m sestamibi tomographic imaging with measurement of first-pass resting LVEF. Twenty-five percent of patients had a prior history of myocardial infarction. First-pass LVEF was measured using a peripheral intravenous injection and a multicrystal gamma camera with standard software. Resting tomographic perfusion defect size (infarct size) was quantitated using previously published methods. Mean LVEF for the study group was 0.60 +/- 0.11. Mean LV infarct size was 5 +/- 11%. For the 1,265 patients (65% of the study group) with no measurable perfusion defect, the prevalence of a normal (> or = 0.50) LVEF was 96% (1,212 of 1,265 patients). For patients with a measurable defect (n = 690, 35%), the inverse linear correlation with LVEF was highly significant (r = -0.60, p <0.0001) but with wide confidence limits (SEE = 10 LVEF points), thereby limiting the predictive value in individual patients. Thus, in the absence of known cardiomyopathy, valvular heart disease, or left bundle branch block, patients without a quantifiable resting perfusion defect are highly likely to have a normal resting LVEF and may not require determination of LV function. For patients with resting perfusion defects, LVEF cannot be predicted with confidence and should therefore be measured.